控股股东筹划重大事项，太龙药业12月4日起继续停牌

Core Viewpoint - Tai Long Pharmaceutical (600222) announced a potential change in control due to its major shareholder, Zhengzhou Tai Rong Industrial Investment Co., Ltd., planning to transfer shares, leading to a suspension of trading since December 2 [1] Group 1: Company Announcement - The company stated that the major shareholder is actively promoting the significant matter and negotiating transaction terms with the counterparties [1] - The involved parties are required to complete relevant internal approval procedures, which may delay the resumption of trading [1] - The company anticipates that it will not resume trading on December 4 and has applied for an extension of the trading suspension, expected to last no more than three trading days [1]